5α-reductase inhibitors and the risk of cancer-related mortality in men with prostate cancer

JAMA Oncology

Volumn 1, Issue 3, 2015, Pages 314-320

  Azoulay, Laurent ^a,b   Eberg, Maria ^a   Benayoun, Serge ^c   Pollak, Michael ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

CHEMICALLY INDUCED; EPIDEMIOLOGY; FACTUAL DATABASE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

5-ALPHA REDUCTASE INHIBITORS; DATABASES, FACTUAL; DUTASTERIDE; FINASTERIDE; GREAT BRITAIN; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84965090533     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.0387     Document Type: Article

References (31)

1. Burnett AL, Wein AJ. Benign prostatic hyperplasia in primary care: what you need to know. J Urol. 2006;175(3, pt 2):S19-S24.
2. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224.
3. Andriole GL, Bostwick DG, Brawley OW, et al; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202.
4. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98(16):1128-1133.
5. Thompson IM, Tangen CM, Goodman PJ, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007;177(5):1749-1752.
6. Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99(18):1366-1374.
7. Lucia MS, Darke AK, Goodman PJ, et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila). 2008;1(3):167-173.
8. FDA Drug Safety Communication. 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. US Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm. Accessed October 23, 2013.
9. Ørsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol. 2011;60(4):691-698.
10. Hong SK, Oh JJ, Lee S, et al. Association of 5α-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy. Prostate. 2012;72(11):1187-1192.
11. Murtola TJ, Kujala PM, Tammela TL. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers. Prostate. 2013;73(9):923-931.
12. Thompson IM Jr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369(7):603-610.
13. LeFevre M. A role for finasteride in the prevention of prostate cancer? N Engl J Med. 2013;369(7):670-671.
14. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45(5):419-425.
15. United Kingdom National Health Service. Read codes. http://systems.hscic.gov.uk/data/uktc/readcodes. Accessed June 12, 2013.
16. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779):766-768.
17. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med. 1999;21(3):299-304.
18. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol. 2000;49(6):591-596.
19. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23(5):686-689.
20. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4-14.
21. Office of Population Censuses and Surveys. Classification of Surgical Operations and Procedures, Fourth Revision, 1987. London, England: OPCS; 1987.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
23. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract. 2010;11:1.
24. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488-495.
25. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-522.
26. Fine J, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
27. Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ. 2013;346:f3406.
28. Preston MA, Wilson KM, Markt SC, et al. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014;174(8):1301-1307.
29. Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf. 2013;22(2):168-175.
30. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst. 2001;93(23):1822-1823.
31. Cancer incidence and mortality in the United Kingdom and constituent countries, 2002-04. Health Stat Q. 2007;35(35):78-83.